N-(1-benzylpiperidine-4-yl)-4-phenoxybenzamide | 363627-78-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(1-benzylpiperidine-4-yl)-4-phenoxybenzamide
• 英文别名: N-(1-benzylpiperidin-4-yl)-4-phenoxybenzamide
• CAS: 363627-78-5
• 化学式: C₂₅H₂₆N₂O₂
• 分子量: 386.494
• InChiKey: WISVTTNTMGFFRP-UHFFFAOYSA-N

物化性质

• 沸点：
  554.6±50.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-苯氧基苯甲酸 在 盐酸 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 N-(1-benzylpiperidine-4-yl)-4-phenoxybenzamide
  参考文献：
  名称：

  4-苯氧基苯甲酰胺类化合物及其制备方法和应 用

  摘要：

  4-苯氧基苯甲酰胺类化合物及其制备方法和应用，涉及4-苯氧基苯甲酰胺类化合物。所述4-苯氧基苯甲酰胺类化合物为通式（I）的化合物或其药物衍生物、前药和立体异构体：所述4-苯氧基苯甲酰胺类化合物可在制备治疗肿瘤药物中应用。所述肿瘤包括肝癌、肺癌和乳腺癌等。

  公开号：

  CN103709094B

文献信息

• Design, synthesis, and pharmacological evaluation of indole-piperidine amides as Blood−brain barrier permeable dual cholinesterase and β-secretase inhibitors
  作者：Razia Banoo、Vijay K. Nuthakki、Bhagyashri N. Wadje、Ankita Sharma、Sandip B. Bharate

  DOI：10.1016/j.ejmech.2024.116131

  日期：2024.2

  causes has prompted interest in discovering multi-target directed ligands (MTDLs) to slow down the disease's progression. Herein we report the synthesis and biological evaluation of indole-piperidine amides as MTDLs for AD. The 5,6-dimethoxy-indole -(2-(1-benzylpiperidine) carboxamide () inhibits hAChE and hBACE-1 with IC values of 0.32 and 0.39 μM, respectively. The MTDL is a mixed-type inhibitor of both

  杂环化合物在治疗药物的发现中发挥着至关重要的作用。阿尔茨海默病（AD）是一种难以理解的散发性神经退行性疾病，涉及多种病理途径。目前的单靶点小分子未能解决 AD 的根本原因，这引发了人们对发现多靶点定向配体 (MTDL) 以减缓疾病进展的兴趣。在此，我们报道了吲哚哌啶酰胺作为 AD MTDL 的合成和生物学评价。 5,6-dimethoxy-indole -(2-(1-benzylpiperidine) carboxamide () 抑制 hAChE 和 hBACE-1，IC 值分别为 0.32 和 0.39 μM。MTDL 是 hAChE 和 hBACE 的混合型抑制剂-1，值分别为 0.26 μM 和 0.46 μM MD 模拟研究表明，AChE 和 BACE-1 在与 . AD 临床前模型的研究。
• Evaluation of Novel<i>N</i>-(piperidine-4-yl)benzamide Derivatives as Potential Cell Cycle Inhibitors in HepG2 Cells
  作者：Jin Hou、Wei Zhao、Zhi-Ning Huang、Shao-Mei Yang、Li-Juan Wang、Yu Jiang、Zhong-Shi Zhou、Man-Yi Zheng、Ji-Li Jiang、Shan-Hua Li、Fu-Nan Li

  DOI：10.1111/cbdd.12484

  日期：2015.8

  In this study, a series of novel N‐(piperidine‐4‐yl)benzamide derivatives was designed, synthesized, and evaluated for antitumor activity. Some compounds were found to have potent antitumor activity. In particular, compound 47 showed the most potent biological activity against HepG2 cells, with an IC50 value of 0.25 μm. Western blot analysis demonstrated that compound 47 inhibited the expression of cyclin B1 and p‐Rb and enhanced the expression of p21, p53, Rb, and phospho‐adenosine monophosphate‐activated protein kinase (p‐AMPK). Further, cell cycle arrest was observed by flow cytometry (FCM). In summary, compound 47 was screened to have potential activity for the treatment of hepatocarcinoma via the induction of cell cycle arrest by a p53/p21‐dependent pathway.
• SUBSTITUTED AMINO-AZA-CYCLOALKANES USEFUL AGAINST MALARIA
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1322612A1

  公开（公告）日：2003-07-02
• [EN] SUBSTITUTED AMINO-AZA-CYCLOALKANES USEFUL AGAINST MALARIA<br/>[FR] AMINO-AZA-CYCLOALCANES SUBSTITUES UTILES CONTRE LA MALARIA
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2002024649A1

  公开（公告）日：2002-03-28

  The invention relates to novel compounds which are substituted amino-aza-cycloalkane derivatives of the general formula I. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of general formula I and especially their use as inhibitors of the plasmodium falciparum protease plasmepsin II or related aspartic proteases.
• [EN] MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF<br/>[FR] MODULATEURS D'ENZYMES DE MODIFICATION PAR MÉTHYLATION, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
  申请人：CONSTELLATION PHARMACEUTICALS

  公开号：WO2012068589A2

  公开（公告）日：2012-05-24

  Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.